Navigation Links
Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor
Date:1/28/2008

d include up to an additional $280 million over the life of the agreement if all milestones are met. Nycomed will also receive compensation for providing finished product and royalties on sales of Ciclesonide products.

Nycomed retains all rights to Ciclesonide outside the United States and has partnered the product with Teijin Pharmaceuticals in Japan where ALVESCO(R) was launched in June 2007. Nycomed also has rights for the territories outside the United States to certain line extensions and additional products developed by Sepracor under the agreement.

Sepracor develops and markets a range of products in the respiratory field. ALVESCO(R) and Omnaris(TM)complement Sepracor's respiratory portfolio and expand its product pipeline with Ciclesonide line extension programs. These programs include Omnaris(TM) HFA, a hydrofluoroalkane (HFA) metered-dose inhaler Phase II candidate; ALVESCO(R) inhalation solution, a preclinical candidate; and ALVESCO(R) in combination with a long-acting beta-agonist, an early clinical candidate.

"We were looking for a strategic partner both able to commercialise the products and further develop them. With Sepracor we have found that ideal partner," said Hakan Bjorklund, Nycomed's CEO. "This agreement clearly leverages the potential of Ciclesonide that we believe to be one of the most innovative corticosteroids available to patients," he added.

"We are delighted with this agreement, as OMNARIS AQ and ALVESCO HFA represent two new and exciting products for our 1600 person sales force to launch in 2008. We are also pleased with the additional development assets that form part of this ciclesonide franchise," said Adrian Adams, President and Chief Executive Officer of Sepracor. "The ciclesonide franchise adds further strength to our growing pipeline and is commercially synergistic with our XOPENEX(R) and BROVANA(R) franchises. I am particularly pleased that our core strategy of fully leveraging our existing products,
'/>"/>

SOURCE Nycomed International Management AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
2. Neptune Technologies receives GRAS notification in the United States
3. Essilor: New Acquisitions in the United States and Brazil
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Medical Services Begins Working With United States Companies for Distribution of Its Products
6. United Therapeutics Reports Third Quarter 2007 Financial Results
7. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
8. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
9. ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India
10. United BioSource Acquires Caro Research, Leader in Simulation Modeling
11. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 ... the "The World Market for Flow Cytometry ... http://photos.prnewswire.com/prnh/20130307/600769 ... that are now an important component of advanced ... diagnostic instruments for cancer diagnostics, but their newer ...
(Date:8/1/2014)... 2014 The  PROPEL Center  of the  iBIO ... rate of early-stage life sciences companies in ... 15 grants to help Illinois ...   in Chicago .   AdvaMed ... North America , bringing more than 1,000 ...
(Date:8/1/2014)... Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Second quarter sales increased 59% to ... year. , Second quarter EBITDA increased 86% to $21.2 ... year (see table at the end of this release). ... of foreign currency, to between 13% and 16% over 2013, ...
(Date:7/31/2014)... July 31, 2014 Today BioSpace , the leading life ... map campaign spotlighting the life sciences community in Illinois ... Kansas , Michigan , Minnesota ... Ohio and Wisconsin . ... percent of all job postings on BioSpace originating in this region in ...
Breaking Biology Technology:The World Market for Flow Cytometry in IVD Applications 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Midwest Biotech Leaders Featured On BioSpace Map 2
... China, July 7 /PRNewswire-Asia-FirstCall/ -- China Clean,Energy Inc. ... "Company"),a producer of biodiesel fuel and environmentally-friendly specialty ... Republic of China,("PRC"), today announced that business conditions ... the first quarter, driven by improved demand and,higher ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... developing breakthrough treatments for human disease, announced today that it ... LX1032 , the company,s oral drug candidate for managing ... LX1032 is designed to reduce serotonin production in patients ...
... The Leukemia & Lymphoma Society (LLS) and The ... initiative to develop stable and immortalized Waldenstrom,s macroglobulinemia (WM) ... researchers to test potential new treatments for the disease. ... lymphoma, characterized by B-lymphocytes in the bone marrow, and ...
Cached Biology Technology:China Clean Energy Provides Business Update 2China Clean Energy Provides Business Update 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research 2The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research 3
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... how the brain processes speech, potentially increasing the ... at The University of Texas at Dallas. , ... Ear and Hearing , researchers demonstrated for the ... brain,s recognition of speech sounds. , Noise-induced hearing ... affecting an estimated 15 percent of Americans between ...
(Date:7/31/2014)... step has been made to help better identify and treat ... abnormal narrowing and enlarging of medium sized arteries in the ... other organs causing damage. In a new report appearing in ... , scientists provide evidence that that FMD may not be ... show a connection to abnormalities of bones and joints, as ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... farming and relieve the pressure on overexploited fish stocks. ... fish escape? Researchers at the University of Gothenburg have ... are urging caution:,-Until further notice transgenic fish should be ... at the Department of Zoology, University of Gothenburg. ...
... A research report featured on the cover of the September ... http://www.fasebj.org ) describes how Australian scientists developed a new gene ... to transport their cargo into our cells. As a result ... cell,s nucleus far more efficiently than in the past, raising ...
... from natural coal deposits in the Gulf of Alaska ... the Exxon Valdez tanker catastrophe. This clearly disproves the ... observed environmental damage. PAH pollutants were blamed for the ... Alaska. Then a dispute erupted over the origins of ...
Cached Biology News:Risks involved with transgenic fish 2Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes 2Bioavailable contaminants come from the Exxon Valdez oil catastrophe 2
... a fixative useful for routine procedures. Hollandes ... stable and will decalcify small bone specimens. ... be stained successfully with most stains, and ... red blood cell membranes and cosinophil and ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... the complete enterprise microarray informatics platform for microarray ... Acuity once and use it forever without paying ... Quality Acuity has all the analysis tools ... data, from quality control statistics and normalization, all ...
... As the world of discovery races ever ... you on the fast track. So our constant ... help accelerate your research. Thats why our Biomek ... platform thats as advanced as it is flexible. ...
Biology Products: